Assessment of quality of data submitted for NICE technology appraisals over two decades

Osipenko,L.,Ul-Hasan,S. A.,Winberg,D.,Prudyus,K.,Kousta,M.,Rizoglou,A.,Rustignoli,I.,van der Maas,L.
DOI: https://doi.org/10.1136/bmjopen-2023-074341
IF: 3.006
2024-02-14
BMJ Open
Abstract:Background The National Institute for Health and Care Excellence (NICE) pioneered the Health Technology Assessment (HTA) processes and methodologies. Technology appraisals (TAs) focus on pharmaceutical products and clinical and economic data, which are presented by the product manufacturers to the NICE appraisal committee for decision-making. Uncertainty in data reduces the chance of a positive outcome from the HTA process or requires a higher discount. Objective To investigate the quality of clinical data (comparator, quality of life (QoL), randomised controlled trials (RCTs) and overall quality of evidence) submitted by the manufacturers to NICE. Design This retrospective evaluation analysed active TAs published between 2000 and 2019 (up to TA600). Methods For all TAs, we extracted data from the Assessment Group and Evidence Review Group reports and Final Appraisal Determinations on (1) the quality of submitted RCTs and (2) the overall quality of evidence submitted for decision-making. For single TAs, we also extracted data and its critique on QoL and comparators. Each category was scored for quality and analysed using descriptive statistics. Results 409 TAs were analysed (multiple technology appraisals (MTA)=104, single technology appraisal (STA)=305). In two-thirds of TAs, the overall quality of evidence was either poor (n=224, 55%) or unacceptable (n=41, 10%). In 39% (n=119) of the STAs, the quality of comparative evidence was considered poor, and in 17% (n=51) unacceptable. In 44% (n=135) of STAs, the quality of QoL data was considered poor, 15% (n=47) unacceptable, 33% (n=102) acceptable and 7% (n=21) as good. Over 20 years of longitudinal analysis did not show improvements in the quality of evidence submitted to NICE. Conclusion We found that the primary components of clinical evidence influencing NICE's decision-making framework were of poor quality. It is essential to continue to generate robust clinical data for premarket and postmarket introduction of medicines into clinical practice to ensure they deliver benefits to patients.
medicine, general & internal
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to evaluate the quality of clinical data submitted to the National Institute for Health and Care Excellence (NICE) in the UK during the technology assessment process. Specifically, the study aims to systematically review all active technology assessments (TAs) published by NICE between 2000 and 2019, investigate the key problems in the clinical evidence submitted by manufacturers, and evaluate the quality of this evidence to support decision - making. ### Main problems 1. **Overall quality of clinical data**: - The study found that in two - thirds of the technology assessments, the overall quality of the submitted evidence was poor or unacceptable. - Specifically, the overall evidence quality of 55% of the technology assessments (TAs) was rated as poor, and 10% was rated as unacceptable. 2. **Quality of comparative evidence**: - In 39% of single - technology assessments (STAs), the quality of comparative evidence was considered poor, and 17% was rated as unacceptable. - In 44% of STAs, the quality of quality - of - life (QoL) data was considered poor, and 15% was rated as unacceptable. 3. **Quality of randomized controlled trials (RCTs)**: - More than half of the RCTs were evaluated as being of poor quality or unacceptable. - Specifically, 41% of the RCTs were of poor quality, and 10% were of unacceptable quality. 4. **Longitudinal analysis**: - Longitudinal analysis over the past 20 years shows that the quality of clinical evidence submitted to NICE has not improved significantly. ### Conclusions The study found that the quality of the main clinical evidence components that affect NICE's decision - making framework is poor. In order to ensure that drugs can bring practical benefits to patients before and after marketing, it is crucial to continue to generate high - quality clinical data. Through these analyses, the study emphasizes the importance of improving the quality of clinical evidence in order to reduce uncertainty in the HTA process and improve the accuracy of decision - making.